Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.13 -4.2%	$1.30	$0.86 ▼ $3.78	$258.10M	0.31	3.26 million shs	2.11 million shs
BOLD Boundless Bio	$1.06 -54.1%	$59.97	$1.00 ▼ $4.72	$22.61M	-1.56	100,751 shs	96,520 shs
CRSP CRISPR Therapeutics	$48.64 +2.4%	$39.69	$30.04 ▼ $63.68	$4.10B	1.75	1.87 million shs	5.28 million shs
HALO Halozyme Therapeutics	$52.02 -0.4%	$55.92	$42.01 ▼ $70.51	$6.43B	1.19	1.74 million shs	3.61 million shs
MNTA Momenta Pharmaceuticals	$52.48	$52.44	$12.21 ▼ $52.53	$6.25B	1.71	1.94 million shs	N/A

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	-4.24%	-7.38%	-3.00%	-17.52%	-51.50%
BOLD Boundless Bio	+1.44%	+1.93%	-4.09%	-27.74%	-72.74%
CRSP CRISPR Therapeutics	+2.42%	+6.78%	+34.96%	+46.77%	-9.94%
HALO Halozyme Therapeutics	-0.36%	-1.48%	-7.07%	-15.92%	-0.65%
MNTA Momenta Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	3.358 of 5 stars	4.5	1.0	0.0	0.0	2.2	3.3	0.6
BOLD Boundless Bio	1.771 of 5 stars	3.1	2.0	0.0	0.0	0.0	1.7	1.3
CRSP CRISPR Therapeutics	2.9283 of 5 stars	4.3	1.0	0.0	0.0	2.0	2.5	0.6
HALO Halozyme Therapeutics	4.8327 of 5 stars	3.1	1.0	0.0	4.4	2.5	2.5	4.4
MNTA Momenta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.90	Moderate Buy	$8.44	647.30% Upside
BOLD Boundless Bio	2.25	Hold	$4.00	279.15% Upside
CRSP CRISPR Therapeutics	2.53	Moderate Buy	$71.75	47.51% Upside
HALO Halozyme Therapeutics	2.17	Hold	$61.90	18.99% Upside
MNTA Momenta Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ALLO, CRSP, HALO, MNTA, and BOLD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	CRSP CRISPR Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$105.00
6/27/2025	CRSP CRISPR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$86.00
6/27/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$65.00
6/26/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
6/26/2025	CRSP CRISPR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$82.00
6/2/2025	BOLD Boundless Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00
5/29/2025	HALO Halozyme Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00
5/28/2025	BOLD Boundless Bio	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$15.00 ➝ $3.00
5/27/2025	BOLD Boundless Bio	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/21/2025	CRSP CRISPR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$86.00 ➝ $86.00
5/20/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00 ➝ $81.00

(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$20K	12,358.25	N/A	N/A	$2.01 per share	0.56
BOLD Boundless Bio	N/A	N/A	N/A	N/A	$6.76 per share	N/A
CRSP CRISPR Therapeutics	$37.31M	112.59	N/A	N/A	$22.64 per share	2.15
HALO Halozyme Therapeutics	$1.02B	6.31	$4.64 per share	11.22	$2.86 per share	18.19
MNTA Momenta Pharmaceuticals	$23.87M	261.69	N/A	N/A	$4.59 per share	11.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$257.59M	-$1.23	N/A	N/A	N/A	N/A	-52.98%	-41.28%	8/6/2025 (Estimated)
BOLD Boundless Bio	-$65.36M	N/A	N/A	N/A	N/A	N/A	-41.60%	-34.53%	N/A
CRSP CRISPR Therapeutics	-$366.25M	-$4.52	N/A	N/A	N/A	-1,023.64%	-20.08%	-17.13%	8/4/2025 (Estimated)
HALO Halozyme Therapeutics	$444.09M	$3.76	13.84	8.36	0.35	44.76%	136.91%	26.05%	8/5/2025 (Estimated)
MNTA Momenta Pharmaceuticals	-$290.05M	-$3.03	N/A	N/A	N/A	-757.61%	-61.44%	-45.28%	N/A

Latest ALLO, CRSP, HALO, MNTA, and BOLD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ALLO Allogene Therapeutics	-$0.28	-$0.28	N/A	-$0.28	$0.00 million	N/A
5/9/2025	Q1 2025	BOLD Boundless Bio	-$0.68	-$0.71	-$0.03	-$0.71	N/A	N/A
5/6/2025	Q1 2025	CRSP CRISPR Therapeutics	-$1.27	-$1.58	-$0.31	-$1.58	N/A	N/A
5/6/2025	Q1 2025	HALO Halozyme Therapeutics	$0.98	$1.11	+$0.13	$0.93	$231.21 million	$264.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
BOLD Boundless Bio	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
MNTA Momenta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	9.71	9.71
BOLD Boundless Bio	0.35	22.15	22.15
CRSP CRISPR Therapeutics	N/A	15.64	15.64
HALO Halozyme Therapeutics	3.13	8.39	7.30
MNTA Momenta Pharmaceuticals	N/A	6.38	6.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
BOLD Boundless Bio	N/A
CRSP CRISPR Therapeutics	69.20%
HALO Halozyme Therapeutics	97.79%
MNTA Momenta Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
BOLD Boundless Bio	21.10%
CRSP CRISPR Therapeutics	4.10%
HALO Halozyme Therapeutics	2.90%
MNTA Momenta Pharmaceuticals	3.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	218.73 million	189.86 million	Optionable
BOLD Boundless Bio	207	22.39 million	17.66 million	No Data
CRSP CRISPR Therapeutics	473	86.36 million	82.82 million	Optionable
HALO Halozyme Therapeutics	390	123.22 million	119.65 million	Optionable
MNTA Momenta Pharmaceuticals	131	119.03 million	N/A	Optionable

CRSP, HALO, ALLO, MNTA, and BOLD Headlines

Recent News About These Companies

Stephanie Schonewald

October 31, 2024 | ipwatchdog.comI

J&J, with adult approval in sight, posts adolescent myasthenia gravis data on $6.5B FcRn blocker

October 17, 2024 | fiercebiotech.comF

J&J launches gMG market bid with nipocalimab filing

September 2, 2024 | pharmaphorum.comP

Johnson & Johnson Files for First FDA OK of Nipocalimab

August 31, 2024 | marketwatch.com

Impact of Bleeding Complications on Outcomes After Percutaneous Coronary Interventions

April 12, 2024 | medscape.comM

Acquired patents aid J&J defense of top-selling drug from biosimilar challenge

March 30, 2023 | biopharmadive.comB

Genoptix, Momenta Shares Headed for Gains

February 28, 2023 | thestreet.com

Momenta Pharma Competitor Lodges Ethics Complaint Against FDA Boss, WSJ Reports

August 13, 2022 | xconomy.comX

Patent infringement cases move to the fast lane in India

June 13, 2022 | thepharmaletter.comT

Johnson & Johnson, Momenta Pharma file lawsuit against Natco, Mylan in US

May 25, 2022 | msn.com

Eastman Kodak, Rambus: After-Hours Trading

April 30, 2022 | thestreet.com

Innovation leader

April 8, 2022 | udel.eduU

Momenta Pharmaceuticals, Inc. Common Stock (MNTA)

August 3, 2021 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Addition by Subtraction: Intel’s New Strategy Energizes Investors
By Jeffrey Neal Johnson | June 27, 2025
View Addition by Subtraction: Intel’s New Strategy Energizes Investors
Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
By Leo Miller | June 14, 2025
View Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
HSAs for Gym Memberships? These 3 Fitness Stocks Could Soar
By Chris Markoch | June 24, 2025
View HSAs for Gym Memberships? These 3 Fitness Stocks Could Soar
Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY
By Thomas Hughes | June 11, 2025
View Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY

BOLD, HALO, CRSP, ALLO, and MNTA Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.13 -0.05 (-4.24%)

As of 06/30/2025 04:00 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Boundless Bio NASDAQ:BOLD

Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.

CRISPR Therapeutics NASDAQ:CRSP

$48.64 +1.15 (+2.42%)

As of 06/30/2025 04:00 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Halozyme Therapeutics NASDAQ:HALO

$52.02 -0.19 (-0.36%)

As of 06/30/2025 04:00 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Momenta Pharmaceuticals NASDAQ:MNTA

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. The company's biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. The company has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time